Letters
Idiopathic pulmonary fibrosis
Underestimating treatment benefit of lung transplantation for idiopathic pulmonary fibrosis
BMJ 2014; 348 doi: https://doi.org/10.1136/bmj.g24 (Published 06 January 2014) Cite this as: BMJ 2014;348:g24
This article has a correction. Please see:
- P Riddell, respiratory registrar1,
- D Eaton, consultant in lung transplant surgery1,
- A B Miller, professor of respiratory medicine2,
- A U Wells, professor of respiratory medicine3,
- J J Egan, professor of respiratory/transplant medicine1
- 1Advanced Lung Disease and Transplant Programme, Mater Misericordiae University Hospital, Dublin, Republic of Ireland
- 2Academic Respiratory Unit, School of Clinical Sciences, Bristol University, Bristol, UK
- 3Interstitial Lung Disease Unit, Royal Brompton Hospital and National Heart and Lung Institute, London, UK
- priddell{at}mater.ie
Dempsey and Miller drew attention to the inadequacy of medical treatments for idiopathic pulmonary fibrosis (IPF) and the optimism provided by the emergence of pirfenidone.1However, only a cursory note was given to lung transplantation, which seems to have been dismissed by the authors, who describe patients as “too frail or old” with “serious …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.